Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amyloid inhibitors and beta-sheet breakers.

Claudio Soto1, Lisbell Estrada

  • 1Protein Misfolding Disorders Laboratory, Department of Neurology, University of Texas Medical Branch, Galveston, TX, USA.

Sub-Cellular Biochemistry
|February 16, 2005
PubMed
Summary

Beta-sheet breakers are a novel drug class designed to prevent amyloid-beta peptide misfolding, a key process in Alzheimer's disease. This approach shows promise for combating the devastating neurodegenerative effects of Alzheimer's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

α-Synuclein overexpression increases the tropism of pre-formed fibrils and MSA-patient derived seeds towards oligodendroglia.

Acta neuropathologica communications·2026
Same author

Long-Term Outcomes From a Decade of Donation After Circulatory Death Heart Transplantation in Australia.

JACC. Heart failure·2026
Same author

Limited transmission of cervid prions to nonhuman primates provides insights into the zoonotic potential of chronic wasting disease.

Science advances·2026
Same author

Creutzfeldt-Jakob disease is an Alzheimer's disease-related dementia.

Trends in molecular medicine·2026
Same author

Single-nucleus brain transcriptomics reveals microglia dysfunction in multiple system atrophy.

Nature communications·2026
Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

Area of Science:

  • Neuroscience
  • Drug Discovery
  • Biochemistry

Background:

  • Alzheimer's disease pathology involves amyloid-beta peptide misfolding and aggregation.
  • Misfolded amyloid-beta forms neurotoxic oligomers and insoluble brain deposits.
  • These aggregates are central to Alzheimer's disease pathogenesis.

Purpose of the Study:

  • To review the therapeutic potential of beta-sheet breakers for Alzheimer's disease.
  • To summarize evidence supporting beta-sheet breakers as a treatment strategy.
  • To evaluate the efficacy of targeting amyloid-beta misfolding.

Main Methods:

  • Review of existing scientific literature on beta-sheet breakers.
  • Analysis of data on amyloid-beta peptide aggregation and neurotoxicity.

Related Experiment Videos

  • Assessment of drug candidates designed to inhibit beta-sheet formation.

    • Main Results:

    • Beta-sheet breakers are designed to bind amyloid-beta peptide.
    • These drugs aim to block or reverse the pathological misfolding process.
    • Evidence suggests this approach can interfere with amyloid formation.

    Conclusions:

    • Beta-sheet breakers represent a promising new class of drugs for Alzheimer's.
    • Targeting amyloid-beta misfolding offers a potential therapeutic avenue.
    • Further research supports beta-sheet breakers as candidates to combat Alzheimer's disease.